Supplementary Figure S2 from MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
Le résumé fourni par la source
Supplementary Figure S2. In vitro characterization of MEN1309/OBT076. A) ELISA assay showed that both the unconjugated and DM4-conjugated antibodies were able to bind FcγRIIIA with the same affinity (n=2). B) FACS binding experiment on THP-1 cell line, performed by titrating unlabeled antibody with a constant amount of labelled antibody, showed high binding affinity of MBH1309/OBT076 to CD205 expressed on the cell surface with no affinity loss after conjugation (N=2). C) In vitro ADCC bioluminescence assay showed that, despite the ability to bind FcγRIIIA, MBH1309/OBT076 didn't induce any ADCC response. D) In vitro CDC assay on Raji cancer cell lines showed no CDC activity of MBH1309/OBT076 when incubated with purified human complement. On the contrary, Rituximab (used as positive control), showed a strong induction of CDC activity.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Supplementary Figure S2 from MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
- Date Crossref
- 03/04/2023
- Éditeur
- American Association for Cancer Research (AACR)
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.